Table 1 Patient and tumor characteristics
non-BRCA1/2(n = 70) | BRCA1 (n = 33) | BRCA2 (n = 22) | Sporadic (n = 128) | ||
|---|---|---|---|---|---|
Estrogen receptor | |||||
ER+ | 8.6% | 42.4% | 90.9% | 83.6% | |
ER- | 21.4% | 57.6% | 9.1% | 16.4% | |
Progesterone receptor | |||||
PR+ | 65.7% | 21.2% | 72.7% | 61.7% | |
PR- | 34.3% | 78.8% | 27.3% | 38.3% | |
HER2 status | |||||
HER2+ | 14.3% | 9.1% | 4.5% | 16.4% | |
HER2- | 85.7% | 90.1% | 95.5% | 83.6% | |
Lymph node | |||||
LN+ | 41.4% | 45.5% | 63.6% | 39.8% | |
LN- | 52.9% | 48.5% | 31.8% | 58.6% | |
NA | 5.7% | 6.1% | 4.5% | 1.6% | |
Tumor size | |||||
Mean tumor size, mm [±SD] | 25 [±18] | 23 [±10] | 25 [±13] | 25 [±16] | |
Histologic grade | |||||
Grade 1 | 17.1% | 9.1% | 9.1% | 25.0% | |
Grade 2 | 40% | 21.2% | 50.0% | 37.5% | |
Grade 3 | 28.6% | 54.5% | 31.8% | 22.7% | |
NA | 14.3% | 15.2% | 9.1% | 14.8% | |
Tumor type | |||||
Invasive ductal carcinoma | 78.6% | 84.8% | 86.4 % | 82.0% | |
Invasive lobular carcinoma | 12.9% | 3.0% | 9.1 % | 9.4% | |
Mucinous carcinoma | - | - | - | 1.6% | |
Medullary carcinoma | 1.4 % | 6.1% | - | 0.8% | |
Tubular carcinoma | - | - | - | 2.3% | |
Metaplastic carcinoma | 1.4 % | - | - | - | |
Other | - | 6.1 % | - | 1.6% | |
NA | 5.7 % | - | 4.5% | 2.3% | |
Age | |||||
Median age, years [range] | 50 [29–86] | 42 [25–74] | 43.5 [28–72] | 61 [27–95] | |
< 50 years | 47.1% | 63.6% | 68.2% | 16.4% | |
≥ 50 years | 52.9% | 36.4% | 31.8% | 83.6% | |
Menupause status | |||||
Premenopausal | 52.9% | 60.6% | 68.2% | 23.4% | |
Perimenopausal | 2.9% | - | 4.5% | 11.7% | |
Postmenopausal | 38.6% | 36.4% | 22.7% | 60.9% | |
Other | 2.9% | - | - | 1.6% | |
NA | 2.9% | 3.0% | 4.5% | 2.3% |